Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma
INTRODUCTION:<br>Mesothelioma remains a lethal cancer. To date, systemic therapy with pemetrexed and a platinum drug remains the only licensed standard of care. As the median survival for patients with mesothelioma is 12.1 months, surgery is an important consideration to improve survival and/o...
Main Authors: | Lim, E, Darlison, L, Edwards, J, Elliott, D, Fennell, DA, Popat, S, Rintoul, RC, Waller, D, Ali, C, Bille, A, Fuller, L, Ionescu, A, Keni, M, Kirk, A, Koh, P, Lau, K, Mansy, T, Maskell, NA, Milton, R, Muthukumar, D, Pope, T, Roy, A, Shah, R, Shamash, J, Tasigiannopoulos, Z, Taylor, P, Treece, S, Ashton, K, Harris, R, Joyce, K, Warnes, B, Mills, N, Stokes, EA, Rogers, C, MARS 2 Trialists |
---|---|
Format: | Journal article |
Language: | English |
Published: |
BMJ Publishing Group
2020
|
Similar Items
-
Extended Pleurectomy/Decortication for Malignant Pleural Mesothelioma: Humanitas’s Experience
by: Giuseppe Mangiameli, et al.
Published: (2021-10-01) -
Feasibility and safety of extended pleurectomy/decortication for malignant pleural mesothelioma. A single group experience
by: Francesco Falanga, et al.
Published: (2022-10-01) -
Strategies to reduce morbidity following pleurectomy and decortication for malignant pleural mesothelioma
by: Patrick Bou‐Samra, et al.
Published: (2023-09-01) -
Extended pleurectomy/decortication and hyperthermic intraoperative intrapleural cisplatin perfusion for malignant pleural mesotheliomaCentral MessagePerspective
by: Kenichi Okubo, MD, PhD, et al.
Published: (2023-12-01) -
Systematic Review and Meta-Analysis of Pleurectomy/Decortication versus Extrapleural Pneumonectomy in the Treatment of Malignant Pleural Mesothelioma
by: Federica Danuzzo, et al.
Published: (2022-09-01)